An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia

University of Colorado Denver (CU Denver)

Status and phase

Completed

Phase 4

Conditions

Friedreich Ataxia

Treatments

Drug: Placebo & Citalopram

Drug: bupropion & Citalopram

Drug: Placebo & Placebo

Drug: Bupropion & Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT01716221

11-1141

Details and patient eligibility

About

The purpose of this study is to document the clinical effects of bupropion and citalopram in a single subject with Friedreich Ataxia.

Full description

This is a double blind study with a single subject to objectively document the clinical effects of bupropion and citalopram in a single patient with Friedreich Ataxia (FA), whose disorder symptoms have improved with the use of these medications.

Enrollment

1 patient

Sex

Female

Volunteers

No Healthy Volunteers

Inclusion criteria

Friedreich Ataxia

Exclusion criteria

Unable to provide Informed Consent

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Triple Blind

1 participants in 4 patient groups, including a placebo group

Bupropion & Citalopram

Experimental group

Description:

100mg Bupropion \& 20mg Citalopram taken orally one time per day or 100mg Bupropion \& 10mg Citalopram taken orally one time per day or 50mg Bupropion \& 20mg Citalopram taken orally one time per day 0r 50mg Bupropion \& 10mg Citalopram taken orally one time per day

Treatment:

Drug: bupropion & Citalopram

Bupropion & Placebo

Active Comparator group

Description:

100mg Bupropion \& Placebo taken orally one time per day or 50mg Bupropion \& Placebo taken orally one time per day

Treatment:

Drug: Bupropion & Placebo

Placebo & Citalopram

Active Comparator group

Description:

Placebo \& 20mg Citalopram taken orally one time per day or Placebo \& 10mg Citalopram taken orally one time per day